01
Cash & equivalents increased 45.6%
Cash & equivalents changed +45.6% from the comparable as-filed period.
$312.8M→$455.4MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTTaysha Gene Therapies, Inc.'s latest supported as-filed period reports revenue of $0, 100.0% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +45.6% from the comparable as-filed period.
Net income changed -73.5% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating income changed -77.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
TSHA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-344610SEC ↗8-KAug 11, 2026Period Aug 11, 20260001193125-26-344594SEC ↗4Jul 10, 2026Period Jul 10, 20260001665124-26-000013SEC ↗8-KJun 25, 2026Period Jun 24, 20260001193125-26-282855SEC ↗8-KJun 22, 2026Period Jun 22, 20260001193125-26-276738SEC ↗4Jun 2, 2026Period Jun 1, 20260001709418-26-000002SEC ↗4Jun 2, 2026Period Jun 1, 20260001238120-26-000008SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 10, 2026Filed Jul 10, 2026 | Nagendran SukumarPresident and Head of R&D | Open Market SaleDirect | 200,000 | $6 | $1.2M | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +91.8% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Revenue changed -100.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed +82.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001891712-26-000002